279 related articles for article (PubMed ID: 14532267)
41. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis.
Rosenberg RD
Fed Proc; 1985 Feb; 44(2):404-9. PubMed ID: 3155697
[TBL] [Abstract][Full Text] [Related]
42. Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa.
Austin RC; Rachubinski RA; Ofosu FA; Blajchman MA
Blood; 1991 May; 77(10):2185-9. PubMed ID: 2029579
[TBL] [Abstract][Full Text] [Related]
43. Role of arginine 129 in heparin binding and activation of antithrombin.
Desai U; Swanson R; Bock SC; Bjork I; Olson ST
J Biol Chem; 2000 Jun; 275(25):18976-84. PubMed ID: 10764763
[TBL] [Abstract][Full Text] [Related]
44. Mechanism of heparin activation of antithrombin. Evidence for reactive center loop preinsertion with expulsion upon heparin binding.
Huntington JA; Olson ST; Fan B; Gettins PG
Biochemistry; 1996 Jul; 35(26):8495-503. PubMed ID: 8679610
[TBL] [Abstract][Full Text] [Related]
45. The region of antithrombin interacting with full-length heparin chains outside the high-affinity pentasaccharide sequence extends to Lys136 but not to Lys139.
Arocas V; Turk B; Bock SC; Olson ST; Björk I
Biochemistry; 2000 Jul; 39(29):8512-8. PubMed ID: 10913257
[TBL] [Abstract][Full Text] [Related]
46. A coagulation pathway on bovine aortic segments leading to generation of Factor Xa and thrombin.
Stern DM; Nawroth PP; Kisiel W; Handley D; Drillings M; Bartos J
J Clin Invest; 1984 Dec; 74(6):1910-21. PubMed ID: 6439737
[TBL] [Abstract][Full Text] [Related]
47. Evolution of serpin specificity: cooperative interactions in the reactive-site loop sequence of antithrombin specifically restrict the inhibition of activated protein C.
Hopkins PC; Pike RN; Stone SR
J Mol Evol; 2000 Nov; 51(5):507-15. PubMed ID: 11080374
[TBL] [Abstract][Full Text] [Related]
48. Mechanism of acceleration of antithrombin-proteinase reactions by low affinity heparin. Role of the antithrombin binding pentasaccharide in heparin rate enhancement.
Streusand VJ; Björk I; Gettins PG; Petitou M; Olson ST
J Biol Chem; 1995 Apr; 270(16):9043-51. PubMed ID: 7721817
[TBL] [Abstract][Full Text] [Related]
49. A comparison of three heparin-binding serine proteinase inhibitors.
Pratt CW; Whinna HC; Church FC
J Biol Chem; 1992 May; 267(13):8795-801. PubMed ID: 1315739
[TBL] [Abstract][Full Text] [Related]
50. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin.
Nagase H; Enjyoji K; Minamiguchi K; Kitazato KT; Kitazato K; Saito H; Kato H
Blood; 1995 Mar; 85(6):1527-34. PubMed ID: 7888673
[TBL] [Abstract][Full Text] [Related]
51. Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide.
Quinsey NS; Whisstock JC; Le Bonniec B; Louvain V; Bottomley SP; Pike RN
J Biol Chem; 2002 May; 277(18):15971-8. PubMed ID: 11854268
[TBL] [Abstract][Full Text] [Related]
52. The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin.
Björk I; Jackson CM; Jörnvall H; Lavine KK; Nordling K; Salsgiver WJ
J Biol Chem; 1982 Mar; 257(5):2406-11. PubMed ID: 6977539
[TBL] [Abstract][Full Text] [Related]
53. Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan.
Mauray S; de Raucourt E; Talbot JC; Dachary-Prigent J; Jozefowicz M; Fischer AM
Biochim Biophys Acta; 1998 Sep; 1387(1-2):184-94. PubMed ID: 9748565
[TBL] [Abstract][Full Text] [Related]
54. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.
Fuchs HE; Trapp HG; Griffith MJ; Roberts HR; Pizzo SV
J Clin Invest; 1984 Jun; 73(6):1696-703. PubMed ID: 6202716
[TBL] [Abstract][Full Text] [Related]
55. The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin.
Yuan QP; Walke EN; Sheehan JP
Biochemistry; 2005 Mar; 44(9):3615-25. PubMed ID: 15736971
[TBL] [Abstract][Full Text] [Related]
56. Heparin is a major activator of the anticoagulant serpin, protein Z-dependent protease inhibitor.
Huang X; Rezaie AR; Broze GJ; Olson ST
J Biol Chem; 2011 Mar; 286(11):8740-51. PubMed ID: 21220417
[TBL] [Abstract][Full Text] [Related]
57. Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1 to P14 region of the putative reactive bond loop of the inhibitor.
Björk I; Ylinenjärvi K; Olson ST; Bock PE
J Biol Chem; 1992 Jan; 267(3):1976-82. PubMed ID: 1730729
[TBL] [Abstract][Full Text] [Related]
58. Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor.
Björk I; Nordling K; Larsson I; Olson ST
J Biol Chem; 1992 Sep; 267(27):19047-50. PubMed ID: 1388162
[TBL] [Abstract][Full Text] [Related]
59. Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.
Rashid Q; Singh P; Abid M; Jairajpuri MA
J Thromb Thrombolysis; 2012 Aug; 34(2):251-9. PubMed ID: 22453684
[TBL] [Abstract][Full Text] [Related]
60. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions.
Schreuder HA; de Boer B; Dijkema R; Mulders J; Theunissen HJ; Grootenhuis PD; Hol WG
Nat Struct Biol; 1994 Jan; 1(1):48-54. PubMed ID: 7656006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
